🇺🇸 CEDAZURIDINE in United States

1,405 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Transfusion — 179 reports (12.74%)
  2. Full Blood Count Abnormal — 178 reports (12.67%)
  3. Fatigue — 163 reports (11.6%)
  4. Platelet Count Decreased — 143 reports (10.18%)
  5. Death — 141 reports (10.04%)
  6. Product Use Issue — 137 reports (9.75%)
  7. Therapy Interrupted — 137 reports (9.75%)
  8. White Blood Cell Count Decreased — 124 reports (8.83%)
  9. Inappropriate Schedule Of Product Administration — 105 reports (7.47%)
  10. Haemoglobin Decreased — 98 reports (6.98%)

Source database →

CEDAZURIDINE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is CEDAZURIDINE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for CEDAZURIDINE in United States?

Marketing authorisation holder not available in our data.